Abstract
Introducción. El intercambio plasmático (IP) se ha convertido en una alternativa terapéutica para múltiples enfermedades. Cada día hay más evidencia científica que apoya el uso de esta terapia en varias enfermedades neurológicas. Es importante registrar la experiencia local en IP para conocer la respuesta de nuestra población a la terapia.
Objetivo. Describir la experiencia del Hospital Universitario San Ignacio en IP realizado a pacientes con enfermedades neurológicas durante un período de cuatro años.
Materiales y métodos. Estudio observacional retrospectivo en el que se describe a los pacientes, la técnica de la terapia, las complicaciones y la respuesta clínica de los pacientes con enfermedades neurológicas tratados con IP.
Resultados. Se realizaron 106 sesiones de IP en 16 pacientes. El promedio de edad de los pacientes fue de 43 años, el 81% de los pacientes eran de sexo femenino. El 83% de las sesiones fueron indicadas por miastenia
gravis, el resto por síndrome de Guillain-Barré, neuromielítis óptica, neuropatía motora multifocal y encefalitis autoinmune. Todas las sesiones fueron realizadas por técnica de filtración transmembrana. El promedio de recambios plasmáticos realizado fue 1.3. Se registraron 26 complicaciones en 20 sesiones de IP. La respuesta neurológica de los pacientes a la terapia fue la esperada y similar a la reportada en la literatura médica.
Conclusión. Según la experiencia de la institución, el IP es una terapia segura y eficaz en pacientes con enfermedades neurológicas.
References
WARD DM. Conventional apheresis therapies: a review. J Clin Apher. 2011; 26(5):230-8.
SCHWAB PJ, FAHEY JL. Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med. 1960; 263:574- 9.
SCHWAB PJ, OKUN E, FAHEY JL. Reversal of retinopathy in Waldenstrom’s macroglobulinemia by plasmapheresis. A report of two cases. Arch Ophthalmol. 1960; 64:515-21.
BALOGUN RA, KAPLAN A, WARD DM, OKAFOR C, BURNSTM, TORLONI AS, MACIK BG, ABDEL-RAHMAN EM. Clinical applications of therapeutic apheresis. J Clin Apher. 2010; 25(5):250-64.
CHHIBBER V, WEINSTEIN R. Evidence-based review of therapeutic plasma exchange in neurological disorders. Semin Dial. 2012; 25(2):132-9.
LEHMANN HC, HARTUNG HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immunemediated neuropathies. J Neuroimmunol 2011;231:61–69.
Drachman DB. Myasthenia gravis. N Engl J Med. 1994; 330:1797-1810.
LENNON VA, KRYZER TJ, GRIESMANN GE, ET AL. Calciumchannel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med.1995; 332:1467-1474.
WILLISON HJ. The immunobiology of Guillin_Barre’ syndromes. J Perpher Nerv Syst. 2205; 10:94-112.
JARIUS S, PAUL F, FRANCIOTTA D, WATERS P, ZIPP F, HOHLFELD R, VINCENT A, WILDEMANN B. Mechanism of disease: aquaporin-4 antibodies in neuromyelitis óptica. Nat Clin Pract Neurol. 2008; 4:202-214.
GAJDOS P, SIMON N, DE ROHAN-CHABOT P, RAPHAEL JC, GOULON M. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med. 1983; 12: 939–942.
GAJDOS P, CHEVRET S, TOYKA K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; 4: CD002275.
GAJDOS P, CHEVRET S, CLAIR B, TRANCHANT C, CHASTANG C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789–796
RONAGER J, RAVNBORG M, HERMANSEN I, VORSTRUP S. Immunoglobulin treatment versus plasma exchange in patients
with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25:967–973.
EL-BAWAB H, HAJJAR W, RAFAY M, BAMOUSA A, KHALIL A, ALKATTAN K. Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols. Eur J Cardiothorac Surg 2009;35:392–397.
DADA MA, KAPLAN AA. Plasmapheresis treatment in Guillain- Barre syndrome: potential benefit over IVIg in patients with
axonal involvement. Ther Apher Dial 2004;8:409–412.
RAPHAËL JC, CHEVRET S, HUGHES RA, ANNANE D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst
Rev. 2012;7:CD001798.
FRENCH COOPERATIVE GROUP ON PLASMA EXCHANGE IN GUILLAIN- BARRE’ SYNDROME. Plasma exchange in Guillain- Barre’ syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barre’ Syndrome. Ann Neurol. 1992;32:94–97.
WATANABE S, NASHIMA I, MISU T, MIYAZAWA I, SHIGA Y, FUJIHARA K, ITOYAMA Y. Therapeutic efficacy of plasma Exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128–132.
BONNAN M, VALENTINO R, OLINDO S. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum
disorder. Mult Scler 2009;15:487–492.
WANG KC, WANG SJ, LEE CL, CHEN SY, TSAI CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci
;18:43–46.
GWATHMEY K, BALOGUN RA, BURNS T. Neurologic indications for TPE: 2011 update. J Clin Apher. 2012;27(3):138-45.
CORTESE I, CHAUDHRY V, SO YT, CANTOR F, CORNBLATH DR, RAE-GRANT A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011; 76(3):294-300.
SCHWARTZ J, WINTERS JL, PADMANABHAN A, BALOGUN RA, DELANEY M, LINENBERGER ML, SZCZEPIORKOWSKI ZM, WILLIAMS ME, WU Y, SHAZ BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013 Jul;28(3):145-284.
YÜCESAN C, ARSLAN O, ARAT M, YÜCEMEN N, AYYILDIZ E, ILHAN O, MUTLUER N. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci. 2007; 36(1):103-7.
KAYNAR L, ALTUNTAS F, AYDOGDU I, TURGUT B, KOCYIGIT I, HACIOGLU SK, ISMAILOGULLARI S, TURGUT N, ERKURT MA, SARI I, OZTEKIN M, SOLMAZ M, ESER B, ERSOY AO, UNAL A, CETIN M. Therapeutic plasma exchange in patients with neurologic diseases: Retrospective multicenter study. Transfus Apher Sci. 2008; 38(2):109-15.
KAYA E, KEKLIK M, SENCAN M, YILMAZ M, KESKIN A, KIKI I, ERKURT MA, SIVGIN S, KORKMAZ S, OKAN V, DOĞU MH, UNAL A, CETIN M, ALTUNTAŞ F, ILHAN O. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis. Transfus Apher Sci. 2013; 48(3):349-52.
NOGALES-GAETE J, VALENZUELA D, LIENDO F, VIDAL P, GIL G, SÁEZ D. Plasmapheresis in neurological diseases. Experience
in 140 procedures in 47 patients. Rev Med Chil. 2004;132(3):295- 8.
SALTIEL C. Apheresis Activity in Venezuela. J Clin Apher 2005;20:95–100.
LAZO-LANGNER A, ESPINOSA-POBLANO I, TIRADOCÁRDENAS N, RAMÍREZ-ARVIZU P, LÓPEZ-SALMORÁN J, PEÑALOZA-RAMÍREZ P, SÁNCHEZ-GUERRERO SA. Therapeutic plasma exchange in Mexico: experience from a single institution. Am J Hematol. 2002;70:16-21.
CÓRDOBA JP, LARRARTE C, RUIZ A. Is anticoagulation required in plasmapheresis? A University Hospital Experience in Bogota,
Colombia. Transfus Apher Sci. 2013; 48(3):301-5.
VINCENT A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002; 2: 797–804.
HOCH W, MCCONVILLE J, HELMS S, NEWSOM-DAVIS J, MELMS A, VINCENT A. Auto-antibodies to the receptor tyrosine kinase
MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365–368.
SKEIE GO, APOSTOLSKI S, EVOLI A, GILHUS NE, ILLA I, HARMS L, HILTON-JONES D, MELMS A, VERSCHUUREN J, HORGE HW; EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010; 17(7):893-902.
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome.
Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 1997;349:225–230.
MCLEOD BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in
therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19(1):157-67.
ANAYA F. Manual de aféresis terapéutica basada en la evidencia. Grupo editorial Nefrología de Sociedad Española de Nefrología; 2012:1-210.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.